Physician profile
Leah A Balch
NPI 1225451925
$9,396.88
in general payments reported to CMS, 2019-2025
33 companies · $3,731 in 2025
The $3,731 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,277 · 2022: $1,238 · 2023: $975 · 2024: $2,176 · 2025: $3,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,314 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,400 · Travel and Lodging: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,313.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,400.00 |
| Travel and Lodging | $168.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,321.28 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,233.77 | 2021-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $617.84 | 2021-2025 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $599.24 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $575.64 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Neurelis, INC. | $513.49 | 2023-2025 | Valtoco |
| Ucb, INC. | $503.49 | 2024-2025 | Briviact, Nayzilam, Rystiggo |
| Ardelyx, INC. | $200.99 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $181.44 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $179.54 | 2021-2023 | |
| Argenx US, INC. | $177.58 | 2024-2025 | Vyvgart |
| Aimmune Therapeutics, INC. | $165.02 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $158.55 | 2021-2024 | Talicia |
| Lundbeck LLC | $155.90 | 2024-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $103.31 | 2024-2025 | Ultomiris |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $84.46 | 2021-2025 | Ocaliva |
| Pfizer INC. | $70.52 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $68.23 | 2025 | |
| Genzyme Corporation | $65.52 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $59.21 | 2025 | |
| Merck Sharp & Dohme LLC | $56.70 | 2021-2023 | Dificid |
| Sandoz INC. | $45.00 | 2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $41.61 | 2023-2024 | Idacio |
| Daiichi Sankyo INC. | $38.85 | 2025 | Injectafer |
| Sk Life Science, INC. | $32.12 | 2025 | |
| Mallinckrodt Hospital Products INC. | $29.99 | 2025 | Acthar |
| Novo Nordisk INC | $19.31 | 2025 | Wegovy |
| Eisai INC. | $17.83 | 2024 | |
| Lilly USA, LLC | $16.48 | 2025 | Omvoh |
| Intra-Sana Laboratories | $16.41 | 2022 | |
| Braintree Laboratories, INC. | $16.19 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.59 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Balch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.